Volume | 0 |
|
|||||
News | - |
Etf Name | Etf Symbol | Market | Stock Type |
---|---|---|---|
Kelly Strategic ETF Trust Hotel & Lodging Sector ETF | HOTL | NYSE | Exchange Traded Fund |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
Trades | Etfs Traded | Average Volume |
---|---|---|
0 | 0 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | USD |
Kelly Strategic ETF Trust Hotel & Lodging Sector ETF Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
729.20k | - | - | - | 24.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Kelly Strategic
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
HOTL Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a ¿passive management¿ investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified. |